Biosafety Principles and Practices for the Veterinary Diagnostic Laboratory

Kozlovac, Joseph P.; Schmitt, Beverly J.

doi:10.1007/978-1-4939-2004-4_3

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, the placebo group received drinking water without nicergoline. The animals' drinking water was routinely acidified using HCl to avoid the growth of pathogenic microorganisms; this acidification process is a sanitation measure typically used in vivariums and one which is safe for laboratory animals [16][17][18].…”

Section: Nicergoline Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Role of nicergoline in corneal wound healing in diabetic rats

Portela

Moreno

Ribeiro³

et al. 2021

BMC Ophthalmol

View full text Add to dashboard Cite

Background To investigate the effect of nicergoline on the rate of complete corneal ulcer reepithelialization (CCUR) in diabetic rats with diabetic keratopathy. Methods Forty-eight streptozotocin-induced diabetic rats were randomly divided into two groups. The experimental group (n = 24) received nicergoline (10 mg.kg− 1.day− 1), while the control group (n = 24) received a placebo. A corneal epithelial defect was induced using a corneal diamond burr, and defect area was compared at time points of 0, 12, 24, 48 and 72 h after the injury using image analysis software. The probability of CCUR within 72 h was assessed using the Kaplan–Meier survival analysis log-rank test. Results When compared, 4 of the 24 rats (17%) in the placebo group and 12 of the 24 rats (50%) in the nicergoline group were found to have CCUR within 72 h (log-rank = 0.027). Cox regression analysis found no effect of the covariates blood glucose (P = 0.601) or weight (P = 0.322) on the corneal reepithelialization (survival) curve. Conclusions Nicergoline increased wound healing rates relative to placebo and may therefore be investigated as a treatment option in diabetic keratopathy.

show abstract

Section: Nicergoline Treatmentmentioning

confidence: 99%

“…It acts as an α-1 adrenergic antagonist, acetylcholinesterase inhibitor, dopaminergic agonist and PI3K/AKT pathway activator; it also increases SP and NGF levels and exhibits antioxidant properties. Such properties have inspired research into its use in corneal wound healing [13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Role of nicergoline in corneal wound healing in diabetic rats

Portela

Moreno

Ribeiro³

et al. 2021

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In general, biosafety in a mobile laboratory is achieved by optimising laboratory practices, equipment safety and qualification of the laboratory staff [12][13][14]. For example, neither cultivation nor enrichment of infectious material are foreseen in the mobile laboratory as this would dramatically increase biosafety risks as well as biosecurity risks [15].…”

Section: Biosafety and Biosecurity Managementmentioning

confidence: 99%

Mobile diagnostics in outbreak response, not only for Ebola: a blueprint for a modular and robust field laboratory

et al. 2015

View full text Add to dashboard Cite

We established a modular, rapidly deployable laboratory system that provides diagnostic support in resource-limited, remote areas. Developed as a quick response asset to unusual outbreaks of infectious diseases worldwide, several of these laboratories have been used as part of the World Health Organization response to the Ebola virus outbreaks by teams of the ‘European Mobile Lab’ project in West Africa since March 2014. Within three days from deployment, the first European mobile laboratory became operational at the Ebola Treatment Unit (ETU) in Guéckédou, southern Guinea. Deployment in close proximity to the ETU decreased the turnaround time to an average of 4 h instead of several days in many cases. Between March 2014 and May 2015, more than 5,800 samples were tested in this field laboratory. Further EMLab units were deployed to Nigeria, Liberia and Sierra Leone in the following months of the Ebola outbreak. The technical concept of the EMLab units served as a blueprint for other mobile Ebola laboratories which have been set up in Mali, Côte d’Ivoire, Sierra Leone and other countries in West Africa. Here, we describe design, capabilities and utility of this deployable laboratory system for use in response to disease outbreaks, epidemiological surveillance and patient management.

show abstract

“…An established PCR-based strategy to increase the detection sensitivity thresholds of low-copy number DNA targets is the nested PCR, although this higher sensitivity needs to be balanced against the associated increased risk of cross contamination of samples. Thus, the use of nested PCR approaches, as for any diagnostics techniques, requires very strict good practice standard conditions for molecular analysis and an effective quality assurance and control (Costa et al, 2013a , 2014b ; Kozlovac and Schmitt, 2014 ; Saunders and Sharp, 2014 ). Previous studies found no significant improvements in the detection of MTC members in animal tissue samples when using nested PCR assays, including with real-time PCR formats (Wards et al, 1995 ; Taylor et al, 2007 ; Thacker et al, 2011 ).…”

Section: Re-emerging Strategies To Uncover Animal-relevant Mtc Membermentioning

confidence: 99%

Standing of nucleic acid testing strategies in veterinary diagnosis laboratories to uncover Mycobacterium tuberculosis complex members

Costa

Botelho

Couto

et al. 2014

Front. Mol. Biosci.

View full text Add to dashboard Cite

Nucleic acid testing (NAT) designate any molecular approach used for the detection, identification, and characterization of pathogenic microorganisms, enabling the rapid, specific, and sensitive diagnostic of infectious diseases, such as tuberculosis. These assays have been widely used since the 90s of the last century in human clinical laboratories and, subsequently, also in veterinary diagnostics. Most NAT strategies are based in the polymerase chain reaction (PCR) and its several enhancements and variations. From the conventional PCR, real-time PCR and its combinations, isothermal DNA amplification, to the nanotechnologies, here we review how the NAT assays have been applied to decipher if and which member of the Mycobacterium tuberculosis complex is present in a clinical sample. Recent advances in DNA sequencing also brought new challenges and have made possible to generate rapidly and at a low cost, large amounts of sequence data. This revolution with the high-throughput sequencing (HTS) technologies makes whole genome sequencing (WGS) and metagenomics the trendiest NAT strategies, today. The ranking of NAT techniques in the field of clinical diagnostics is rising, and we provide a SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis with our view of the use of molecular diagnostics for detecting tuberculosis in veterinary laboratories, notwithstanding the gold standard being still the classical culture of the agent. The complementary use of both classical and molecular diagnostics approaches is recommended to speed the diagnostic, enabling a fast decision by competent authorities and rapid tackling of the disease.

show abstract

Biosafety Principles and Practices for the Veterinary Diagnostic Laboratory

Cited by 3 publications

References 5 publications

Role of nicergoline in corneal wound healing in diabetic rats

Role of nicergoline in corneal wound healing in diabetic rats

Mobile diagnostics in outbreak response, not only for Ebola: a blueprint for a modular and robust field laboratory

Standing of nucleic acid testing strategies in veterinary diagnosis laboratories to uncover Mycobacterium tuberculosis complex members

Contact Info

Product

Resources

About